Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, ICMR Centre for Advanced Research on Diabetes, Chennai, India.
Emcure Pharmaceuticals Ltd., Pune, India.
Diabetes Metab Syndr. 2022 Nov;16(11):102632. doi: 10.1016/j.dsx.2022.102632. Epub 2022 Sep 28.
To study the frequency of iron deficiency anemia (IDA) in individuals with type 2 diabetes mellitus (T2DM) seen at tertiary diabetes care centres across India.
This is a retrospective study (January 1, 2017-December 31, 2019), which included 1137 individuals with T2DM, aged ≥18 years, for whom data on glycemic, lipid and haematological parameters were available. Anthropometric measurements were done using standardized techniques. Biochemical investigations included fasting plasma glucose[FPG], post prandial plasma glucose, HbA1c, lipids and serum ferritin and iron wherever feasible.
Of the 1137 individuals included for the study, 117 (10.3%) were categorized as no 'iron deficiency' (ID) group [normal hemoglobin: male ≥13 g/dl, female ≥12 g/dl and normal serum ferritin ≥70 μg/L], 123 (10.8%) as ID group [normal hemoglobin and low serum ferritin <70 μg/L)], 447 (39.3%) as IDA group [low haemoglobin: male <13 g/dl, female <12 g/dl and low serum ferritin] and 450 (39.6%) as 'anemia of chronic disease' (ACD) group [low hemoglobin and normal serum ferritin]. The percentage of women having ID (57.7%) and IDA (65.3%) was significantly higher than their male counterparts. ID was most prevalent (61.7%) in the individuals with duration of diabetes <5 years whereas ACD was most prevalent (50.5%) in individuals with long standing diabetes (>10 years). Independent risk factors for IDA were female gender (OR 3.3,95% CI:1.75-6.23, p < 0.001), duration of diabetes (OR 1.05, 95% CI 1.01-1.11, p = 0.028) and FPG (OR 1.01, 95% CI 0.99-1.00, p = 0.018).
There is a need of identifying and monitoring iron status and anemia in patients with T2DM.
研究在印度各地的三级糖尿病护理中心就诊的 2 型糖尿病(T2DM)患者中铁缺乏性贫血(IDA)的频率。
这是一项回顾性研究(2017 年 1 月 1 日至 2019 年 12 月 31 日),纳入了 1137 名年龄≥18 岁的 T2DM 患者,这些患者有血糖、血脂和血液学参数的数据。采用标准化技术进行人体测量。生化检查包括空腹血糖[FPG]、餐后血糖、HbA1c、血脂和血清铁蛋白和铁,在可行的情况下。
在纳入研究的 1137 名患者中,117 名(10.3%)被归类为无“铁缺乏”(ID)组[正常血红蛋白:男性≥13 g/dl,女性≥12 g/dl,正常血清铁蛋白≥70μg/L],123 名(10.8%)为 ID 组[正常血红蛋白和低血清铁蛋白<70μg/L],447 名(39.3%)为 IDA 组[低血红蛋白:男性<13 g/dl,女性<12 g/dl,低血清铁蛋白]和 450 名(39.6%)为“慢性病性贫血”(ACD)组[低血红蛋白和正常血清铁蛋白]。患有 ID(57.7%)和 IDA(65.3%)的女性比例明显高于男性。在糖尿病病程<5 年的患者中,ID 最为常见(61.7%),而在病程较长的患者(>10 年)中,ACD 最为常见(50.5%)。IDA 的独立危险因素是女性(OR 3.3,95%CI:1.75-6.23,p<0.001)、糖尿病病程(OR 1.05,95%CI 1.01-1.11,p=0.028)和 FPG(OR 1.01,95%CI 0.99-1.00,p=0.018)。
需要在 T2DM 患者中识别和监测铁状态和贫血。